NEW! March 10, 2010: Cylex™ Elects Richard A. Sandberg as Independent Director

February 1, 2010: Cylex™ Launches Its New Corporate Identity

January 12, 2010: Cylex™ Awarded New CPT Code for its ImmuKnow^® Assay

December 28, 2009: Cylex™ CEO Presides Over NASDAQ Closing Bell Ceremony

October 20, 2009: Deloitte Announces 2009 Technology Fast 500™

September 10, 2009: Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board

May 31, 2009: Three Independent Studies Include the ImmuKnow^® Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients

May 31, 2009: Living Donor Kidney Transplants Using Alemtuzumab Pre-conditioning and Tacrolimus Monotherapy: Long-term Safety and Efficacy

May 30, 2009: Serial Monitoring with ImmuKnow^® is Useful in the Risk Assessment of Kidney Transplant Recipients

May 30, 2009: Immune Monitoring with ImmuKnow^® in Islet Transplantation May Prove Useful in Reducing the Potential Risks of Rejection, Infection and Other Complications Following Transplant

April 24, 2009: An Independent Study Reports on the Utility of ImmuKnow^®, the Cylex™ Immune Cell Function Assay, for Monitoring Heart Transplant Recipients

October 1, 2008: Cylex™ Receives ISO 13485:2003 and 9001:2000 Quality Certifications

August 28, 2008: Patented ImmuKnow^® Immune Cell Function Assay to be Studied in Italian Liver Transplant Patients

August 28, 2008: Cylex Announces Plan for Multi-Center Trial of ImmuKnow^® Assay in South Korea

August 21, 2008: New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation

August 21, 2008: New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients

August 21, 2008: Cylex Announces Significant Expansions and Reassignments of Personnel

June 2, 2008: University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients

June 1, 2008: Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients

May 30, 2008: Multiple Independent Studies Report on Use of Cylex's Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients

April 11, 2008: Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection

April 10, 2008: Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease in Lung Transplant Patients

April 9, 2008: Independent Studies Report on Possible Roles for Cylex's Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients

April 9, 2008: Cylex Announces Brad Stewart as President of the Company

February 19, 2008: New Independent Research Study Indicates that Cylex’s ImmuKnow Test May Identify Kidney Transplant Patients At Risk For Early Acute Rejection

January 24, 2008: Cylex, Inc. Announces New Board Member and Management Change